Molecular Docking Study of Some Nucleoside Analogs against Main Protease of SARS-CoV-2
Objectives: The global pandemic outburst of SARS-CoV-2 in December 2019 infected a large number of people and hasclaimed a significant number of lives. Given the lack of proper therapeutic agents or vaccinefor this pandemic disease, the world is faced with a huge challenge of curingthe infected patients. Therefore, the development of potential therapeutic agents against COVID-19 is a dire need of the situation.
Methods: Herein, we utilized molecular docking to explore the inhibitory potential of nine nucleoside analogs, includingTelbivudine, Entecavir, Clevudine, Zalcitabine, Taribavirin, Stavudine, Lamivudine, Cordycepin, and cordycepin triphosphate, against the main protease of SARS-CoV-2.
Results: The binding energy (ΔG) ofthenine nucleoside analogs against the main protease of SARS-CoV-2 were −6.5 Kcal/mole (Telbivudine), −6.8 Kcal/mole (Entecavir), −6.8 Kcal/mole (Clevudine), −5.8 Kcal/mole (Zalcitabine),−6.1 Kcal/ mole (Taribavirin), −6.5 Kcal/mole (Stavudine), −5.7 Kcal/mole (lamivudine),−6.5 Kcal/mole(Cordycepin), and −6.9 Kcal/ mole (Cordycepin triphosphaye).
Conclusion: Although the molecular docking results are promising, further in vitro and in vivo studies are required to understand the mechanism of binding of thesenucleoside analogs to the COVID-19 Protein.
1.Sang P, Tian SH, Meng ZH, Yang LQ. Anti-HIV drug repurposing against SARS-CoV-2. RSC Advances2020;10:15775–83.
2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.Nature Medicine 2020;26:450–5.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 2020;382:727–33.
4. Hoffmann M, Weber HK, Schroeder S, Krüger N, Herrler T, Er-ichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;81:271–80.
5. Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal 2020;10:320–8.
6. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research2020;30:269–71.
7. Yamamoto N, Matsuyama S, Hoshino T, Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. 2020 Apr 8.doi: https://doi. org/10.1101/2020.04.06.026476. [Epub ahead of print].
8. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/ Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci 2020;35:e79.
9. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382:929–36.
10. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 2020;6:28.
11. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;55:105932.
12. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382:1787–99.
13. Wafa T, Mohamed K. Molecular Docking Study of COVID-19 Main Protease with Clinically Approved Drugs. ChemRxiv. 2020 Jun 29. doi: https://doi.org/10.26434/chemrxiv.12318689.v1. [Epub ahead of print].
14. Peele KA, Potla Durthi C, Srihansa T, Krupanidhi S, Ayyagari VS, Babu DJ, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked 2020;19:100345.
15. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395:e30–1.
16. Mothay D, Ramesh KV. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. Virusdisease 2020;31:1–6.
17. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020;14:241–6.
18. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149–50.
19. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto, S. Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study. Preprints. 2020 Mar 13. doi: 10.20944/preprints202003.0226.v1. [Epub ahead of print].
20. Gao K, Nguyen DD, Wang R, Wei GW. Machine intelligence design of 2019-nCoV drugs. bioRxiv. 2020 Feb 4. doi: https://doi. org/10.1101/2020.01.30.927889. [Epub ahead of print].
21. Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem 2020;21:730–8.
22. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58–60.
23. Hall DC Jr, Ji HF. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis 2020;35:101646.
24. Liu X, Wang XJ. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics 2020;47:119–21.
25. Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. 2020 Jan 28. doi: https://doi. org/10.1101/2020.01.27.921627.[Epub ahead of print].
26. Aly OM. Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease. ChemRxiv, 2020 Apr 3. doi: doi.org/10.26434/chemrxiv.12061302. v1. [Epub ahead of print].
27. Sivasankarapillai VS, Pillai AM, Rahdar A, Sobha AP, Das SS, Mitropoulos AC, et al.On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. Nanomaterials 2020;10:852.
28. Belhassan A, Chtita S, Zaki H, Lakhlifi T, Bouachrine M. Molecular docking analysis of N-substituted oseltamivir derivatives with the SARS-Cov-2 main protease. Bioinformation 2020;16:404–10.
29. Huynh T, Wang H, Luan B. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease. Journal of Physical Chemistry Letters 2020;11:4413–20.
30. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends 2020;14:69–71.
31. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candi-date drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020;157:104859.
32. Gentile D, Patamia V, Scala A, Sciortino MT, Piperno A, Rescifina A. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study. Mar Drugs 2020;18:225.
33. Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020;10:313–9.
34. Narkhede RR, Cheke RS, Ambhore JP, Sindhe SD.The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARSCoV-2. Eurasian Journal of Medicine and Oncology 2020;4:185–95.
35. Liu C,Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science 2020;6:315–31.
36. Harismah K, Mirzaei M. Favipiravir: Structural Analysis and Activity against COVID-19 Advance Journal of Chemistry B 2020;2:55–60.
37. Eyer L, Nencka R, de Clercq E, Seley-Radtke K, Růžek D. Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antivir Chem Chemother 2018;26:2040206618761299.
38. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 2016;29:695–747.
39. Mahmoud S, Hasabelnaby S, Hammad SF, Sakr TM. Antiviral Nucleoside and Nucleotide Analogs: A Review. Journal of Advance Pharmaceutical Research 2018;2:73–88.
40. ZandiK, Bassit L, Amblard F, Cox BD,Hassandarvish P, Moghaddam E, et al. Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. Antimicrobial Agents and Chemotheraphy 2019;63:e00397–19.
41. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Review Drug Discovery2013;12:447–64.
42. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Research2009;81:147–55.
43. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al;BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine2006;354:1011–20.
44. Rivkin A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today (Barc)2007;43:201–20.
45. Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Review of Anti-Infective Theraphy2006;4:549–61.
46. Leandro KC, Moreira JC, Farias PA. Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry. J Pharm (Cairo) 2013;2013:495814.
47. Kearney KR, Thornton JJ, Navarro VJ. Taribavirin for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotheraphy2008;9:3243–9.
48. Piscitelli SC, Kelly G, Walker RE, Kovacs J, Falloon J, Davey RT Jr. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43:647–50.
49. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996;51:846–64.
50. Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, et al. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 2018;78:125–35.
51. Ryu E, Son M, Lee M, Lee K, Cho JY, Cho S, et al. Cordycepin is a novel chemical suppressor of Epstein-Barr virus replication. Oncoscience2014;1:866–81.
52. Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin. 3 Biotech 2014;4:1–12.
53. Xia X. Bioinformatics and Drug Discovery. Cur Top Med Chem2017;17:1709–26.
54. Pinzi L, Rastelli G. Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Science2019;20:4331–53.
55. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
56. Vijesh AM, Isloor AM, Telkar S, Arumoli T, Fun HK. Molecular docking studies of some new imidazole derivatives for antimicrobial properties. Arabian Journal of Chemistry 2013;6:197–204.
57. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010;31:455–61.
58. DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystallography 2002;40:82–92.
59. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug discovery Today 2004;9:430–1.
60. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the Novel Coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of Human Transmission. Science China Life Sciences 2020;63:457–60.
61. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020;582:289–93.